STOCK TITAN

Veru Inc - VERU STOCK NEWS

Welcome to our dedicated news page for Veru (Ticker: VERU), a resource for investors and traders seeking the latest updates and insights on Veru.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Veru's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Veru's position in the market.

Rhea-AI Summary
Veru Inc. appoints Dr. Louis Aronne as Chief Medical Advisor to support the advancement of enobosarm, a novel drug for quality weight loss. Dr. Aronne's expertise in obesity treatment enhances Veru's development program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.1%
Tags
management
-
Rhea-AI Summary
Veru Inc. received a delinquency notification from Nasdaq due to non-compliance with filing its Quarterly Report on Form 10-Q. The company has 60 days to submit a plan to regain compliance, with a potential extension until August 19, 2024. The delay was caused by higher estimated research and development expenses, leading to a longer cash runway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
none
-
Rhea-AI Summary
Veru Inc. forms a Scientific Advisory Board to support the development of enobosarm, a novel drug for quality weight loss. The board comprises experts in metabolic diseases, obesity, and muscle preservation, aiming to enhance fat loss while preserving muscle mass.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
management
Rhea-AI Summary
Veru Inc. receives FDA clearance for enobosarm development in combination with GLP-1 drugs for higher quality weight loss, plans to initiate Phase 2b obesity study by April 2024. Completed public offering for net proceeds of $35.2 million, bringing total cash to $40.6 million at December 31, 2023. Company to host conference call and webcast today at 8:00 a.m. ET. Mitchell Steiner, M.D., Chairman, President, and CEO of Veru Inc., emphasizes the critical unmet medical need for higher quality weight loss therapeutics that preserve muscle and augment fat loss with minimal side effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.82%
Tags
earnings
-
Rhea-AI Summary
Veru Inc. (NASDAQ: VERU) has received FDA clearance for its Investigational New Drug (IND) application for a Phase 2b clinical study to evaluate enobosarm, a selective androgen receptor modulator (SARM), in combination with GLP-1 drugs for weight loss. The trial aims to preserve muscle mass and physical function while increasing fat loss in sarcopenic obese or overweight elderly patients. The study is expected to begin by April 2024, with topline results anticipated by the end of 2024. Enobosarm's potential to prevent muscle loss and reduce fat in at-risk patients presents a significant opportunity for the company's innovative medicines in the weight loss, oncology, and viral induced ARDS segments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.2%
Tags
clinical trial
-
Rhea-AI Summary
Veru Inc. announces an update of its Phase 2b clinical program of enobosarm to augment fat loss and avoid muscle loss when combined with GLP-1 drugs for weight loss at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The presentation will be made by Mitchell Steiner, M.D., Chairman, President, and CEO of Veru, on February 14, 2024. The webcast will be accessible through the Investors section of the Company’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.26%
Tags
conferences
Rhea-AI Summary
Veru Inc. (VERU) will host a conference call and audio webcast on February 8, 2024, to discuss its fiscal 2024 first-quarter financial results and provide a business update. The company is a late clinical stage biopharmaceutical company focused on developing novel medicines for obesity, oncology, and viral-induced acute respiratory distress syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
conferences earnings
-
Rhea-AI Summary
Veru Inc. (VERU) submits IND application for enobosarm for obesity treatment, aiming to prevent muscle loss. The company plans a Phase 2b clinical trial to evaluate the safety and efficacy of enobosarm in preventing muscle loss in sarcopenic obese or overweight elderly patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
clinical trial
-
Rhea-AI Summary
Veru Inc. (NASDAQ: VERU) to host investor conference call to discuss recent financing and strategy for developing enobosarm for weight loss, along with an update on the drug pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
conferences
Rhea-AI Summary
Veru Inc. (NASDAQ: VERU) announced the pricing of an underwritten public offering of 45,833,333 shares of its common stock at $0.72 per share, expecting to raise approximately $33 million in gross proceeds. The company is focused on developing medicines for metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.64%
Tags
offering
Veru Inc

Nasdaq:VERU

VERU Rankings

VERU Stock Data

83.09M
71.68M
14.11%
40.8%
6.55%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Miami

About VERU

the female health company/veru healthcare is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. to realize this goal, veru healthcare has three divisions: pharmaceutical and devices, consumer health products, and public sector. for men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout, and sexual dysfunction. women’s health has product candidates for female sexual health and advanced breast and ovarian cancers and markets fc2, a disposable contraceptive device, to ob gyn physicians and is the only female condom approved by fda that offers dual protection against sexually transmitted infections, including hiv/aids and the zika virus, and unintended pregnancy. since the female health company began distributing fc2 in 2007, the product has been shipped to 144 countries